Geert R DHaens
Overview
Explore the profile of Geert R DHaens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
170
Citations
4417
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torres J, DHaens G, Regueiro M, Santana G, Panes J, Vermeire S, et al.
Therap Adv Gastroenterol
. 2025 Mar;
18:17562848251318849.
PMID: 40028509
Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). Objectives: To investigate potential predictors of efficacy in RIVETING. Design: This post hoc analysis included...
2.
Directionality of endoscopic and histologic healing in ulcerative colitis: a prospective pilot study
Hanzel J, Novak G, Jairath V, Zou G, Dong H, Gui X, et al.
Eur J Gastroenterol Hepatol
. 2025 Feb;
37(3):304-307.
PMID: 39919005
Objective: Endoscopic and histologic healing in ulcerative colitis (UC) is hypothesized to progress proximally to distally, with healing of the distal rectosigmoid occurring last. However, this has not been empirically...
3.
de Jong D, Goetgebuer R, Muskens B, Neefjes-Borst E, Gecse K, Lowenberg M, et al.
United European Gastroenterol J
. 2025 Feb;
PMID: 39895228
Background & Aims: Up to 15% of ulcerative colitis (UC) patients with an ileo-anal pouch will develop chronic or antibiotic refractory pouchitis. We aimed to evaluate the efficacy and safety...
4.
Visser E, Luberto A, Heuthorst L, Hompes R, Vermeire S, DHaens G, et al.
J Crohns Colitis
. 2025 Jan;
19(2).
PMID: 39847462
Background: We aimed to evaluate the impact of advanced medical therapies (biologicals and small molecules) on time to colectomy and oncological outcomes in ulcerative colitis (UC). Methods: This cohort study...
5.
Beek K, Mulders L, van Rijn K, Horsthuis K, Tielbeek J, Buskens C, et al.
Eur Radiol
. 2024 Aug;
35(3):1428-1439.
PMID: 39212672
Background: There is an increasing need for objective treatment monitoring in perianal fistulising Crohn's disease (pfCD). Therefore, the magnetic resonance novel index for fistula imaging in CD (MAGNIFI-CD) index has...
6.
Ma C, Feagan B, Wang Z, Zou G, Smith M, Shackelton L, et al.
J Crohns Colitis
. 2024 Jul;
19(1).
PMID: 39030919
Background And Aims: The ileum is the most commonly affected segment of the gastrointestinal tract in Crohn's disease [CD]. We aimed to determine whether disease location affects response to filgotinib,...
7.
van der Does de Willebois E, Bellato V, Duijvestein M, van der Bilt J, van Dongen K, Spinelli A, et al.
Lancet Gastroenterol Hepatol
. 2024 Jul;
9(9):793-801.
PMID: 39025100
Background: Retrospective research suggests that excision of the affected mesentery can improve outcomes after an ileocoecal resection in Crohn's disease. However, prospective data from randomised controlled trials are scarce. We...
8.
Vermeire S, Sands B, Peyrin-Biroulet L, DHaens G, Panes J, Yarur A, et al.
J Crohns Colitis
. 2024 Jun;
18(11):1780-1794.
PMID: 38877972
Background And Aims: Etrasimod is an oral, once daily, selective, sphingosine 1-phosphate [S1P]1,4,5 receptor modulator for the treatment of moderately to severely active ulcerative colitis [UC]. This subgroup analysis evaluated...
9.
Panes J, DHaens G, Sands B, Ng S, Lawendy N, Kulisek N, et al.
United European Gastroenterol J
. 2024 May;
12(6):793-801.
PMID: 38778549
Background And Aims: Tofacitinib is an oral Janus kinase inhibitor for the treatment of ulcerative colitis (UC). We report an integrated summary of tofacitinib safety from the completed global UC...
10.
Peyrin-Biroulet L, Dubinsky M, Sands B, Panes J, Schreiber S, Reinisch W, et al.
J Crohns Colitis
. 2024 Apr;
18(8):1270-1282.
PMID: 38613425
Background And Aims: Pivotal trials in ulcerative colitis have historically excluded patients with isolated proctitis. Etrasimod is an oral, once-daily, selective sphingosine 1-phosphate1,4,5 receptor modulator for the treatment of moderately...